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THE effect of carnitine, a drug that plays an essential role
in mitochondria metabolism, on some of the most impor-
tant human polymorphonuclear leucocytes (PMN) acti-
vation steps including modulation of adhesion molecule
density, reactive oxygen species production, and tumour
necrosis factor-0t (TNF0t) production was investigated.
The capability of carnitine in protecting PMN from deter
ioration on storage was also studied. Data shows that
carnitine exerts considerable effects on all PMN functions
investigated. Although the ultimate effect was often donor
dependent, TNF0t production was exceptional in that
carnitine was able to consistently reduce TNF0t produc-
tion in Staphylococcus aureus stimulated PMN in a clear
dose-dependent fashion. It is concluded that carnitine may
represent a useful active agent in situations characterized
by PMN mobilization/activation.
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Introduction
L- Carnitine gamma- trimethylamino fl hydroxy
butyrate) is an essential component of cellular
metabolism as it plays a pivotal role in transporting
activated long-chain acyl groups across mitochon-
drial membrane for/-oxidation. Although a large
body of data is available on the involvement of
carnitine in cellular metabolism in cardiac and
skeletal muscle, there is much less information on
the effect of carnitine on cells of the immune system,
such as polymorphonuclear leucocytes (PMN).
PMN serve as major effector cells in host defence
and acute inflammation. A PMN leucocytosis and
a PMN accumulation in tissues is a common feature
of many clinical situations where PMN exert their
primary role in controlling the expansion and
dissemination of pathogenic microorganisms.
2
PMN activities, such as their elevation in
number, margination, and extravasation into
inflammed tissues are under the control of a number
of cytokines which also regulate PMN functions in
the inflammatory site. PMN in turn, synthesize and
release numerous immunoregulatory cytokines.
3
Thus, PMN are at the centre of a vast array of
coordinated signals to which they must respond
with a series of finely tuned biochemical and cellular
responses to exert their defensive task. In order to
become fully functioning defensive effectors, PMN
undergo a series of sequentially related events,
among which adhesion to the vascular endothelium
via specialized adhesion molecules and transen-
dothelial migration, destruction of pathogens via
oxidative reactions, and production of cytokines
with immunoregulatory functions are of paramount
importance. 2’3 Since all these functions are con-
ceivably subject to regulation by a cellular
metabolism modulator such as carnitine, a series of
in vitro assays was devised in order to study the
efficiency of carnitine in these diverse steps which
are instrumental for a correct PMN functioning.
Materials and Methods
PMN preparation" To prevent exposure of PMN to
toxic or stimulatory conditions likely to be a
source of artefactual results, the use of density
gradient centrifugation procedures was avoided
whenever possible.
4 Thus, PMN were obtained as
a total leucocyte population from peripheral
blood after lysis of erythrocytes with buffered
ammonium chloride. A second lysis step was
performed if the cell pellet remained visibly red.
PMN were then singled out from other blood
cells using the electronic capabilities of a flow
cytometer (see below). After lysis, PMN were
resuspended in RPMI 1640 medium at a concentra-
tion of 2 x 106/ml and kept .on ice until use. For
experiments aimed at investigating tumour necrosis
factor-cz (TNF) production by PMN, these had to
be purified from peripheral blood using appropriate
density gradient centrifugation, washed and re-
suspended in RPMI 1640 medium supplemented
with 5% foetal bovine serum albumin. Non-
adherent polypropylene tubes were used through-
out all experiments to prevent possible adherence
ofPMN to inner walls with consequent artefactual
selection of PMN subsets.
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Modulation of membrane molecules: PMN from eight
healthy donors were incubated either alone or in
the presence of 1/m chemotactic peptide formyl-
methionyl-leucyl-phenylalanine (FMLP) with in-
creasing amounts of carnitine-a kind gift of
Sigma-Tau, Pomezia, Roma, Italy--(from 12.5
to 100/g/ml in two-fold dilutions) at 37C for 20
min with occasional shaking.
These conditions of time and temperature were
chosen as they had been found suitable in inducing
minimal spontaneous PMN activation while still
allowing PMN to respond to appropriate stimuli.
At the end of incubation time, PMN were washed
free of carnitine in cold phosphate buffered saline
containing 0.1% bovine serum albumin (PBS-BSA)
and immediately stained with the appropriate
amount of phycoerythrin-conjugated (PE) mono-
clonal antibody to CDllb (Dako A/S, Copenhagen,
Denmark) in a single colour immunofluorescence
assay. Incubation lasted 30 min and PMN were
strictly maintained at +4C to prevent further
modulation of membrane molecules. Background
fluorescence was determined with PE mouse IgG.
PMN were finally washed in cold PBS-BSA and
immediately analysed by flow cytometry.
Reactive oxygen species production: Since PMN found in
inflammatory sites are stimulated to produce
reactive oxygen species (ROS),
6 the influence of
carnitine (12.5 to 400 g/ml in two-fold dilutions)
on ROS production was measured by either
unstimulated or phorbol myristate acetate (PMA)
stimulated PMN from ten healthy donors. PMA
was used at 0.1 and i/g/ml. PMN were loaded with
the nonfluorescent fluorescein derivative dichloro-
fluorescei diacetate (DCHF) which is rapidly
oxidized into a fluorescent compound after ROS
contact and so can be measured by flow cytometry.
6
After 20 min at 37C, PMN were washed in cold
PBS-BSA, and immediately analysed by flow
cytometry.
Protection from deterioration on storage: To explore
whether carnitine was able to prolong PMN
lifespan, PMN from six healthy donors were
incubated at 37C for 24 and 48 h (a condition
leading to an ageing dependent metabolic impair-
ment) in the presence of increasing amounts of
carnitine (from 12.5 to 400/g/ml in two-fold
dilutions). At the end of incubation, PMN were
washed and incubated with 5/M rhodamine 123, a
fluorescent probe that stains mitochondria in direct
relationship to their oxidoreductive capabilities,
7
which can be regarded as a direct marker of the
energy-supplying metabolic process. Incubation
lasted 10 min at 37C. PMN were then washed in
cold PBS-BSA, and immediately analysed by flow
cytometry.
Flow cytometry: Flow cytometry analyses were
performed on a Becton Dickinson FACScan using
log amplification for fluorescence signals. Events of
interest, i.e., PMN were electronically gated using
appropriate combinations of forward and side
light scatter, measures of size and granularity,
respectively, PMN, monocytes, lymphocytes and
remnants of lysed erythrocytes each having distinct
light-scattering properties. Thus, PMN can be
gated for measurement of fluorescence intensity
independent of the other cell types. For each
experimental condition, 5000 PMN were counted.
Data were processed with a Consort 30 Data
Management System (Becton Dickinson). Fluor-
escence intensity was quantitated as the mean
channel number of the fluorescence histogram
distribution,
Production of TNF-: For measuring TNF- produc-
tion, PMN had to be purified from other peripheral
blood leucocytes. This was accomplished using a
standard technique including dextran sedimentation
and Ficoll-Hypaque centrifugation.
4 Residual red
cells were lysed by cold buffered ammonium
chloride. One million PMN were incubated with a
preparation of heat-killed Staphylococcus aureus
(2 x 107 cells) in the presence of carnitine (from 50
to 400 #g/ml in two-fold dilutions) at 37C for 18 h.
Controls included PMN alone and PMN plus
carnitine but without S. aureus. At the end of
incubation, preparations were centrifuged, the
supernatant collected and assayed forTNF content
using a commercial TNF ELISA kit (Genzyme Co.
Cambridge, MA, USA) according to the man-
ufacturer’s instructions. PMN from ten healthy
donors were used for this assay. Data were
expressed as pg/ml.
Results
Membrane molecule modulation: As shown in Fig. 1A
and B, carnitine alone exerted detectable et:fects on
CD11b density although a clear dose-effect
relationship was not always evident and the final
result appeared to be donor dependent. However,
all subjects examined showed a behaviour similar
to that depicted in Fig. 1A and B. The
same was true also when PMN were co-stimulated
with FMLP (Fig. lC and D). Thus, the ultimate
effect of carnitine on a given PMN preparation was
essentially the same irrespective of whether PMN
had been primed by FMLP (Fig. 1A and C, and
Fig. 1B and D).
ROS production: Carnitine interfered with ROS
production in all subjects (n 10) and its activity
was fairly consistent in each individual, irrespective
of the presence ofPMA (Fig. 2). The final effect of
the interaction between carnitine and PMN was
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FIG. 1. Effect of incubation of PMN with carnitine (A and B) or with carnitine and /M FMLP (C and D) on CD11b expression. The intensity of
fluorescence (y axis) was computed from a flow cytometry generated histogram and taken as a measure of CD11b density on the PMN membrane.
Sections A and C, and B and D each refer to a single individual. The results represent the two paradigmatic behaviours of all subjects examined.
donor dependent, although two paradigmatic
behaviours could be observed. Low concentrations
of carnitine induced a reduction followed by an
increase in ROS production when PMN exhibited
low basal and low PMA stimulated ROS
production, whereas the opposite was true for PMN
with high basal and high PMA stimulated ROS
production. When PMA was used at 1/,g/ml,
essentially similar results were observed (not
shown).
Protection on storage: The eects of carnitine on PMN
mitochondrial metabolism are shown in Fig. 3.
After a 24 h incubation, carnitine influenced PMN
from different subjects in a variable manner,
although two paradigmatic behaviours could be
observed (Fig. 3A and B). When PMN were
incubated for 48 h, no consistent results could be
obtained (not shown).
TNF production" Carnitine decreased TNF pro-
duction in S. aureus stimulated PMN in a
dose-dependent fashion. Statistical analysis (Stu-
dent’s test for paired samples) indicated a significant
reduction in TNF production starting from
100 #g/ml of carnitine (Fig. 4).
Discussion
The frequent and severe infectious diseases that
occur in subjects whose PMN are functionally
deficient testify to the pivotal role played by PMN
in the host defence against invading pathogens.
2 To
accomplish their defensive activities, PMN must
undergo a series of sequentially related events that
lead them from the bloodstream into the
inflammatory sites. Each step of this cascade of
events is in turn regulated by cellular mechanisms
that must be finely tuned in order to allow ecient
antimicrobial activity. 2’3 In the present paper the
possible effects of carnitine, an essential component
of cellular energy metabolism on some of the
essential steps involved in PMN functioning,
namely adhesion molecule modulation, ROS
production, and TNF production and release have
been investigated. Protection from deterioration on
storage was also studied as a model for PMN
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FIG. 2. Effect of incubation of PMN with carnitine (A and B) or with carnitine and 0.1 /g/ml PMA (C and D) on ROS production. The intensity of
fluorescence (y axis) was computed from a flow cytometry generated histogram and taken as a measure of ROS production. Sections A and C, and
B and D each refer to a single individual. The results represent the two paradigmatic behaviours of all subjects examined.
survival in tissues. The data obtained indicate that
the membrane density of one of the most important
adhesion molecules, beta-2-integrin CD11b,
3 is in
fact modulated by carnitine. Thus, one can
speculate that the interaction between this integrin
and its counter-receptor on endothelial cells is
under the control of carnitine. Since similar effects
were observed also in FMLP primed PMN, it is
conceivable that the activity of carnitine is not
dependent on the induction of an activation status
of PMN.
It must be noticed, however, that the effects of
carnitine varied with each donor and that two main
paradigmatic behaviours could be observed. This
indicates that the ultimate effect of carnitine on
normal resting or activated PMN is dependent upon
the initial status of the cells. Similar considerations
apply when considering the data obtained in ROS
production and protection on storage assays: ROS
are essential for an efficient killing of ingested
micro-organisms while the survival of PMN and
the maintenance of a satisfactory energy metabolism
may be central to more distal effects, i.e., functional
activities. Interestingly, gamma-interferon has been
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proved able to modulate the activity of PMN and
counteract the decline of their functional activities
induced by overnight storage. This suggests that
PMN metabolism can be influenced by pharmacolo-
gically active agents.
TNF production by S. aureus stimulated PMN
gave fairly consistent results. Carnitine was able to
significantly reduce TNFa production in a dose-
dependent manner starting from 100/tg/ml. This
observation appears of particular interest since
TNF is an inflammatory and immunoregulatory
cytokine that has been shown to play an important
role in the pathogenesis of septic shock.
9 Although
the major sources of TNFo are cells of the
mononuclear phagocyte lineage, PMN have recent-
ly been shown to contribute to TNF production
upon appropriate stimulation.3’1 The present
observations confirm and extend those previous
reports demonstrating that normal human PMN
stimulated to produce and release TNF by
common bacteria can be regulated by carnitine.
To the authors’ knowledge, this is the first
demonstration of the capacity of carnitine to
consistently influence the production of cytokinesGranulocytes and carnitine
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FIG. 3. Effect of incubation of PMN with carnitine on protection on
storage. The intensity of fluorescence (y axis) was computed from a flow
cytometry generated histogram and taken as a measure of mitochondria
energy metabolism. Sections A and B each refer to a single individual.
The results represent the two paradigmatic behaviours of all subjects
examined.
in cells of the immune system. If substantiated by
additional studies, it is conceivable that the present
observation will be of relevance in clinical settings
where a reduction ofTNF0 production is desirable.
To summarize, carnitine exerts sizeable effects on
several PMN activities instrumental for the host’s
defence against pathogens. In addition, since a
normal and finely tuned PMN functioning is
essential for preventing tissue damage also in
non-infection driven inflammatory situations, e.g.,
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FIG. 4. Effect of incubation of PMN with carnitine on stimulation of TNF=
production and release by S. aureus. Each data point represents the mean
value obtained from ten subjects. The differences between no carnitine
and carnitine 100, 200 and 400/g/ml were p < 0.05, p < 0.03 and
p < 0.07, respectively. SA S. aureus.
after endothelial damage,
11 it is possible to speculate
that carnitine may represent a useful agent for PMN
regulation.
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